| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
PAHC Stock Overview
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.
Phibro Animal Health Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.00 |
| 52 Week High | US$31.00 |
| 52 Week Low | US$18.63 |
| Beta | 0.58 |
| 1 Month Change | -3.48% |
| 3 Month Change | -8.84% |
| 1 Year Change | -6.15% |
| 3 Year Change | -35.69% |
| 5 Year Change | -25.09% |
| Change since IPO | 17.65% |
Recent News & Updates
Phibro Animal Health (NASDAQ:PAHC) Has Re-Affirmed Its Dividend Of US$0.12
Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of US$0.12 per share on the...
We Discuss Why Phibro Animal Health Corporation's (NASDAQ:PAHC) CEO Compensation May Be Closely Reviewed
Shareholders will probably not be too impressed with the underwhelming results at Phibro Animal Health Corporation...
Shareholder Returns
| PAHC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.3% | -3.7% | -5.8% |
| 1Y | -6.1% | 3.0% | 4.2% |
Return vs Industry: PAHC underperformed the US Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: PAHC underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| PAHC volatility | |
|---|---|
| PAHC Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: PAHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PAHC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,725 | Jack Bendheim | https://www.pahc.com |
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Phibro Animal Health Fundamentals Summary
| PAHC fundamental statistics | |
|---|---|
| Market Cap | US$810.07m |
| Earnings (TTM) | US$48.62m |
| Revenue (TTM) | US$852.82m |
16.7x
P/E Ratio0.9x
P/S RatioIs PAHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAHC income statement (TTM) | |
|---|---|
| Revenue | US$852.82m |
| Cost of Revenue | US$580.89m |
| Gross Profit | US$271.94m |
| Expenses | US$223.32m |
| Earnings | US$48.62m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 09, 2022
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 31.89% |
| Net Profit Margin | 5.70% |
| Debt/Equity Ratio | 174.9% |
How did PAHC perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield40%
Payout RatioValuation
Is Phibro Animal Health undervalued compared to its fair value and its price relative to the market?
16.66x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PAHC ($20) is trading above our estimate of fair value ($13.7)
Significantly Below Fair Value: PAHC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PAHC is good value based on its PE Ratio (16.7x) compared to the US Pharmaceuticals industry average (22.8x).
PE vs Market: PAHC is poor value based on its PE Ratio (16.7x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: PAHC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PAHC is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (2.1x).
Future Growth
How is Phibro Animal Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-3.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAHC's earnings are forecast to decline over the next 3 years (-3.4% per year).
Earnings vs Market: PAHC's earnings are forecast to decline over the next 3 years (-3.4% per year).
High Growth Earnings: PAHC's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PAHC's revenue (3.3% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: PAHC's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PAHC's Return on Equity is forecast to be low in 3 years time (19.7%).
Past Performance
How has Phibro Animal Health performed over the past 5 years?
-10.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAHC has high quality earnings.
Growing Profit Margin: PAHC's current net profit margins (5.7%) are higher than last year (5.4%).
Past Earnings Growth Analysis
Earnings Trend: PAHC's earnings have declined by 10.9% per year over the past 5 years.
Accelerating Growth: PAHC's earnings growth over the past year (12.2%) exceeds its 5-year average (-10.9% per year).
Earnings vs Industry: PAHC earnings growth over the past year (12.2%) underperformed the Pharmaceuticals industry 12.2%.
Return on Equity
High ROE: Whilst PAHC's Return on Equity (20.84%) is high, this metric is skewed due to their high level of debt.
Financial Health
How is Phibro Animal Health's financial position?
Financial Position Analysis
Short Term Liabilities: PAHC's short term assets ($498.6M) exceed its short term liabilities ($152.6M).
Long Term Liabilities: PAHC's short term assets ($498.6M) exceed its long term liabilities ($450.2M).
Debt to Equity History and Analysis
Debt Level: PAHC's net debt to equity ratio (133.3%) is considered high.
Reducing Debt: PAHC's debt to equity ratio has reduced from 334.5% to 174.9% over the past 5 years.
Debt Coverage: PAHC's debt is not well covered by operating cash flow (12.4%).
Interest Coverage: PAHC's interest payments on its debt are well covered by EBIT (5.7x coverage).
Balance Sheet
Dividend
What is Phibro Animal Health current dividend yield, its reliability and sustainability?
2.40%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PAHC's dividend (2.4%) is higher than the bottom 25% of dividend payers in the US market (1.36%).
High Dividend: PAHC's dividend (2.4%) is low compared to the top 25% of dividend payers in the US market (3.57%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, PAHC has been paying a dividend for less than 10 years.
Growing Dividend: PAHC's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40%), PAHC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PAHC's dividends in 3 years are forecast to be well covered by earnings (36.8% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.2yrs
Average management tenure
CEO
Jack Bendheim (74 yo)
34yrs
Tenure
US$4,001,319
Compensation
Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD4.00M) is above average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: PAHC's management team is seasoned and experienced (5.2 years average tenure).
Board Members
Experienced Board: PAHC's board of directors are seasoned and experienced ( 13.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Phibro Animal Health Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Phibro Animal Health Corporation
- Ticker: PAHC
- Exchange: NasdaqGM
- Founded: 1946
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$810.072m
- Shares outstanding: 40.50m
- Website: https://www.pahc.com
Number of Employees
Location
- Phibro Animal Health Corporation
- Glenpointe Centre East
- 3rd Floor
- Teaneck
- New Jersey
- 07666-6712
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/25 06:26 |
| End of Day Share Price | 2022/01/24 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.